Review
Version 1
Preserved in Portico This version is not peer-reviewed
Choice and Duration of Anticoagulation for Venous Thromboembolism
Version 1
: Received: 13 December 2023 / Approved: 14 December 2023 / Online: 14 December 2023 (10:49:49 CET)
A peer-reviewed article of this Preprint also exists.
Malik, A.; Ha, N.B.; Barnes, G.D. Choice and Duration of Anticoagulation for Venous Thromboembolism. J. Clin. Med. 2024, 13, 301. Malik, A.; Ha, N.B.; Barnes, G.D. Choice and Duration of Anticoagulation for Venous Thromboembolism. J. Clin. Med. 2024, 13, 301.
Abstract
Venous thromboembolism (VTE) is a prevalent medical condition with high morbidity, mortality, and associated cost. Anticoagulation remains the main treatment for VTE, though the decision on when, how, and for how long to administer anticoagulants is increasingly complex. This review highlights the different phases of VTE management, special circumstances for consideration such as antiphospholipid syndrome, coronary artery disease, cancer associated thrombus and COVID, and future anticoagulation options. Anticoagulation management will continue to be a complex decision, applying evidence-based medicine to individual patients with the hope to maximize effectiveness while minimizing risks.
Keywords
Venous Thromboembolism; Pulmonary Embolism; Deep Vein Thrombosis; Anticoagulation; cardio-vascular disease
Subject
Medicine and Pharmacology, Cardiac and Cardiovascular Systems
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
